medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университет10.59598/ME-2305-6053-2026-118-1-152-162medecol-1321Research ArticleТЕОРЕТИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАTHEORETICAL AND EXPERIMENTAL MEDICINEОценка экспрессии гена ESR1 in silico при злокачественных новообразованияхIn silico assessment of ESR1 gene expression in malignanciesЧауханП.ChauhanP.

Ландран, шоссе Грейтер Мохали Харар-Банур, сектор 112, Пенджаб, 140307

Landran, Greater Mohali Kharar-Banur Highway, Sector 112, Punjab 140307

admissions@cgc.edu.inКафедра биотехнологии, Технологический колледж Чандигарха, Группа колледжей ЧандигархаИндияDepartment of Biotechnology, Chandigarh College of Technology, Chandigarh Group of CollegesIndia20260507202601152162Copyright © Чаухан П., 20262026Чаухан П.Chauhan P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/1321

Ген рецептора эстрогена 1 (ESR1) играет ключевую роль в регуляции генов, чувствительных к ER, и влияет на многие физиологические процессы. Этот ген кодирует рецептор эстрогена (ERa), который необходим для пролиферации и дифференцировки клеток, и участвует в развитии различных заболеваний, включая остеопороз, а также злокачественных новообразований, таких как рак толстой кишки, яичников, эндометрия и молочной железы. В связи с ассоциацией мутагенной формы ESR1 со многими видами рака, она также исследуется в качестве потенциального биомаркера рака. Наибольшая экспрессия гена ESR1 в тканях обнаружена в основном в тканях, связанных с женскими репродуктивными органами (молочные железы, ткани шейки матки, фаллопиевы трубы, матка и влагалище). В представленном исследовании анализировалась экспрессия ESR1 при злокачественных новообразованиях с использованием инструментов in silico. TNMplot, TIMER2.0, GTEx, GEPIA, TCGA и др. были использованы для изучения дифференциальной экспрессии генов ESR1 при различных видах рака, изучения корреляции генов и оценки прогностического воздействия и выживаемости пациентов. Исследование показало, что опухолевая ткань демонстрирует более высокую экспрессию ESR1, чем нормальные или метастатические ткани. Экспрессия ESR1 была высокой на всех стадиях развития злокачественного новообразования. Наблюдались различия в общей выживаемости при злокачественных новообразованиях молочной железы, шейки матки, матки и яичников. Результаты исследования могут быть полезны при разработке более эффективных таргетных методов лечения, послужить улучшению результатов лечения пациентов и совершенствованию стратегий лечения рака, а аспект совместной экспрессии генов и связанной транскрипции может стать предметом будущих молекулярных исследований.

The Estrogen Receptor 1 (ESR1) gene plays key roles in regulating ER-responsive genes and affects many physiological processes. This gene encodes the estrogen receptor (ERα), which is essential for cellular proliferation and differentiation and is implicated in various malignancies, including osteoporosis, colon, ovarian, endometrial, and breast cancer. Due to the association of the mutagenic form of ESR1 with many types of cancers, it is also being investigated as a potential biomarker for cancers. The bulk tissue expression of the ESR1 gene is found mainly in the tissues associated with female reproductive organs (breast, cervix tissue, fallopian tubes, uterus, and vagina). This study analyzed ESR1 expression in malignancies using in silico tools. TNMplot, TIMER2.0, GTEx, GEPIA, TCGA, etc., were used to investigate differential expression of ESR1 genes across various cancers, explore gene correlations, and assess prognostic impact and survival outcomes in patients. This study revealed that tumor tissue showed higher ESR1 expression than normal or metastatic tissues. ESR1 expression was high in all pathological stages throughout the course of the malignancy. Differential overall survival was observed among breast, cervical, uterine, and ovarian malignancies. Insights from this research could lead to the development of more effective targeted therapies, improving patient outcomes, and advancing cancer treatment strategies. This aspect of gene co-expression and linked transcription may be the subject of future molecular research.

эндокринный рецепторESR1экспрессия генаэндокринная терапияобщая выживаемостьраковые клеткиметастазированиеendocrine receptorESR1gene expressionendocrine therapyoverall survivalcancer cellsmetastasisReferencesAltwegg K.A., Vadlamudi R.K. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor. Target. Antitumor. Ther. 2021; 2 (4): 385-400. https://doi.org/10.37349/etat.2021.00052Altwegg K.A., Vadlamudi R.K. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor. Target. Antitumor. Ther. 2021; 2 (4): 385-400. https://doi.org/10.37349/etat.2021.00052Anderson B.O., Ilbawi A.M., Fidarova E., Weiderpass E., Stevens L., Abdel-Wahab M., Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021; 22 (5): 578-581. https://doi.org/10.1016/S1470-2045(21)00071-1Anderson B.O., Ilbawi A.M., Fidarova E., Weiderpass E., Stevens L., Abdel-Wahab M., Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021; 22 (5): 578-581. https://doi.org/10.1016/S1470-2045(21)00071-1Arumalla K.K., Haince J.F., Bux R.A., Huang G., Tappia P.S., Ramjiawan B., Ford W.R., Vaida M. Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status. Int. J. Mol. Sci. 2024; 25 (23): 13029. https://doi.org/10.3390/ijms252313029Arumalla K.K., Haince J.F., Bux R.A., Huang G., Tappia P.S., Ramjiawan B., Ford W.R., Vaida M. Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status. Int. J. Mol. Sci. 2024; 25 (23): 13029. https://doi.org/10.3390/ijms252313029Bahia W., Soltani I., Haddad A., Soua A., Radhouani A., Mahdhi A., Ferchichi S. Association of genetic variants in Estrogen receptor (ESR)1 and ESR2 with susceptibility to recurrent pregnancy loss in Tunisian women: A case control study. Gene. 2020; 736: 144406. https://doi.org/10.1016/j.gene.2020.144406Bahia W., Soltani I., Haddad A., Soua A., Radhouani A., Mahdhi A., Ferchichi S. Association of genetic variants in Estrogen receptor (ESR)1 and ESR2 with susceptibility to recurrent pregnancy loss in Tunisian women: A case control study. Gene. 2020; 736: 144406. https://doi.org/10.1016/j.gene.2020.144406Blakely B., Shin S., Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem. Pharmacol. 2023; 212: 115552. https://doi.org/10.1016/j.bcp.2023.115552Blakely B., Shin S., Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem. Pharmacol. 2023; 212: 115552. https://doi.org/10.1016/j.bcp.2023.115552Chakraborty B., Byemerwa J., Krebs T., Lim F., Chang C.Y., McDonnell D.P. Estrogen Receptor Signaling in the Immune System. Endocr. Rev. 2023; 44 (1): 117-141. https://doi.org/10.1210/endrev/bnac017Chakraborty B., Byemerwa J., Krebs T., Lim F., Chang C.Y., McDonnell D.P. Estrogen Receptor Signaling in the Immune System. Endocr. Rev. 2023; 44 (1): 117-141. https://doi.org/10.1210/endrev/bnac017Chhabra A., Tripathi A., Rizvi S., Tyagi R.K. Ligand-independent homo-/hetero-dimerization events of ERα and ERβ occur in the cytoplasmic compartment: Evidences from receptor dynamics in live cells. The Journal of Steroid Biochemistry and Molecular Biology. 2025; 247: 106668. https://doi.org/10.1016/j.jsbmb.2024.106668Chhabra A., Tripathi A., Rizvi S., Tyagi R.K. Ligand-independent homo-/hetero-dimerization events of ERα and ERβ occur in the cytoplasmic compartment: Evidences from receptor dynamics in live cells. The Journal of Steroid Biochemistry and Molecular Biology. 2025; 247: 106668. https://doi.org/10.1016/j.jsbmb.2024.106668Chimento A., De Luca A., Avena P., De Amicis F., Casaburi I., Sirianni R., Pezzi V. Estrogen Receptors-Mediated Apoptosis in Hormone- Dependent Cancers. Int. J. Mol. Sci. 2022; 23 (3): 1242. https://doi.org/10.3390/ijms23031242Chimento A., De Luca A., Avena P., De Amicis F., Casaburi I., Sirianni R., Pezzi V. Estrogen Receptors-Mediated Apoptosis in Hormone- Dependent Cancers. Int. J. Mol. Sci. 2022; 23 (3): 1242. https://doi.org/10.3390/ijms23031242Clarke R., Jones B.C., Sevigny C.M., Hilakivi- Clarke L.A., Sengupta S. Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. Cancer Drug Resist. 2021; 4 (4): 762-783. https://doi.org/10.20517/cdr.2021.33Clarke R., Jones B.C., Sevigny C.M., Hilakivi- Clarke L.A., Sengupta S. Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. Cancer Drug Resist. 2021; 4 (4): 762-783. https://doi.org/10.20517/cdr.2021.33Clusan L., Ferrière F., Flouriot G., Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci. 2023; 24 (7): 6834. https://doi.org/10.3390/ijms24076834Clusan L., Ferrière F., Flouriot G., Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci. 2023; 24 (7): 6834. https://doi.org/10.3390/ijms24076834Dai F., Chen G., Wang Y., Zhang L., Long Y., Yuan M., Yang D., Liu S., Cheng Y., Zhang L. Identification of candidate biomarkers correlated with the diagnosis and prognosis of cervical cancer via integrated bioinformatics analysis. OncoTargets and therapy. 2019; 12: 4517-4532. https://doi.org/10.2147/OTT.S199615Dai F., Chen G., Wang Y., Zhang L., Long Y., Yuan M., Yang D., Liu S., Cheng Y., Zhang L. Identification of candidate biomarkers correlated with the diagnosis and prognosis of cervical cancer via integrated bioinformatics analysis. OncoTargets and therapy. 2019; 12: 4517-4532. https://doi.org/10.2147/OTT.S199615Englert-Golon M., Andrusiewicz M., Żbikowska A., Chmielewska M., Sajdak S., Kotwicka M. Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation. Int. J. Mol. Sci. 2021; 22 (12): 6216. https://doi.org/10.3390/ijms22126216Englert-Golon M., Andrusiewicz M., Żbikowska A., Chmielewska M., Sajdak S., Kotwicka M. Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation. Int. J. Mol. Sci. 2021; 22 (12): 6216. https://doi.org/10.3390/ijms22126216Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., Sonntag-Buck V., Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000; 19 (17): 4688- 4700. https://doi.org/10.1093/emboj/19.17.4688Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., Sonntag-Buck V., Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000; 19 (17): 4688- 4700. https://doi.org/10.1093/emboj/19.17.4688Gogola-Mruk J., Pietrus M., Piechowicz M., Milian-Ciesielska K., Głód P., Wolnicka-Glubisz A., Szpor J., Ptak A. Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival. Reprod Biol. 2024; 24 (3): 100917. https://doi.org/10.1016/j.repbio.2024.100917Gogola-Mruk J., Pietrus M., Piechowicz M., Milian-Ciesielska K., Głód P., Wolnicka-Glubisz A., Szpor J., Ptak A. Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival. Reprod Biol. 2024; 24 (3): 100917. https://doi.org/10.1016/j.repbio.2024.100917Honkanen T.J., Tikkanen A., Karihtala P., Mäkinen M., Väyrynen J.P., Koivunen J.P. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Sci. Rep. 2019; 9 (1): 10961. https://doi.org/10.1038/s41598-019-47375-2Honkanen T.J., Tikkanen A., Karihtala P., Mäkinen M., Väyrynen J.P., Koivunen J.P. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Sci. Rep. 2019; 9 (1): 10961. https://doi.org/10.1038/s41598-019-47375-2Hu C., Liu Y., Jiang S., Chen H., Xu H., Hu J., Li C., Xia H. The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors. Clin. Transl. Med. 2020; 10 (2): e49. https://doi. org/10.1002/ctm2.49Hu C., Liu Y., Jiang S., Chen H., Xu H., Hu J., Li C., Xia H. The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors. Clin. Transl. Med. 2020; 10 (2): e49. https://doi. org/10.1002/ctm2.49Ji Y., Zhang R., Han X., Zhou J. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. Eur. J. Med. Chem. 2023; 247: 115077. https://doi.org/10.1016/j.ejmech.2022.115077Ji Y., Zhang R., Han X., Zhou J. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. Eur. J. Med. Chem. 2023; 247: 115077. https://doi.org/10.1016/j.ejmech.2022.115077Johansson Å., Schmitz D., Höglund J., Hadizadeh F., Karlsson T., Ek W.E. Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer. J. Endocr. Soc. 2022; 6 (8): bvac100. https://doi.org/10.1210/jendso/bvac100Johansson Å., Schmitz D., Höglund J., Hadizadeh F., Karlsson T., Ek W.E. Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer. J. Endocr. Soc. 2022; 6 (8): bvac100. https://doi.org/10.1210/jendso/bvac100Koirala N., Dey N., Aske J., De P. Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. Int. J. Mol. Sci. 2022; 23 (12): 6547. https://doi.org/10.3390/ijms23126547Koirala N., Dey N., Aske J., De P. Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. Int. J. Mol. Sci. 2022; 23 (12): 6547. https://doi.org/10.3390/ijms23126547Langdon S.P., Herrington C.S., Hollis R.L., Gourley C. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers (Basel). 2020; 12 (6): 1647. https://doi.org/10.3390/cancers12061647Langdon S.P., Herrington C.S., Hollis R.L., Gourley C. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers (Basel). 2020; 12 (6): 1647. https://doi.org/10.3390/cancers12061647Lee N., Park M.J., Song W., Jeon K., Jeong S. Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer. Int. J. Mol. Sci. 2020; 21 (22): 8807. https://doi.org/10.3390/ijms21228807Lee N., Park M.J., Song W., Jeon K., Jeong S. Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer. Int. J. Mol. Sci. 2020; 21 (22): 8807. https://doi.org/10.3390/ijms21228807Marra A., Trapani D., Ferraro E., Curigliano G. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treat. Res. 2023; 188: 219-235. https://doi.org/10.1007/978-3-031-33602-7_9Marra A., Trapani D., Ferraro E., Curigliano G. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treat. Res. 2023; 188: 219-235. https://doi.org/10.1007/978-3-031-33602-7_9Mangani S., Piperigkou Z., Koletsis N.E., Ioannou P., Karamanos N.K. Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression. FEBS J. 2025; 292 (7): 1558-1572. https://doi.org/10.1111/febs.17270Mangani S., Piperigkou Z., Koletsis N.E., Ioannou P., Karamanos N.K. Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression. FEBS J. 2025; 292 (7): 1558-1572. https://doi.org/10.1111/febs.17270Miziak P., Baran M., Błaszczak E., Przybyszewska-Podstawka A., Kałafut J., Smok- Kalwat J., Dmoszyńska-Graniczka M., Kiełbus M., Stepulak A. Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel). 2023; 15 (19): 4689. https://doi.org/10.3390/cancers15194689Miziak P., Baran M., Błaszczak E., Przybyszewska-Podstawka A., Kałafut J., Smok- Kalwat J., Dmoszyńska-Graniczka M., Kiełbus M., Stepulak A. Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel). 2023; 15 (19): 4689. https://doi.org/10.3390/cancers15194689Nagaraj G., Ma C.X. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. Adv. Ther. 2021; 38 (1): 109-136. https://doi.org/10.1007/s12325-020-01552-2Nagaraj G., Ma C.X. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. Adv. Ther. 2021; 38 (1): 109-136. https://doi.org/10.1007/s12325-020-01552-2Razavi P., Chang M.T., Xu G., Bandlamudi C., Ross D.S., Vasan N., Cai Y., Bielski C.M., Donoghue M.T.A., Jonsson P., Penson A., Shen R., Pareja F., Kundra R., Middha S., Cheng M.L., Zehir A., Kandoth C., Patel R., Huberman K., Smyth L.M., Jhaveri K., Modi S., Traina T.A., Dang C., Zhang W., Weigelt B., Li B.T., Ladanyi M., Hyman D.M., Schultz N., Robson M.E., Hudis C., Brogi E., Viale A., Norton L., Dickler M.N., Berger M.F., Iacobuzio-Donahue C.A., Chandarlapaty S., Scaltriti M., Reis-Filho J.S., Solit D.B., Taylor B.S., Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34 (3): 427-438. https://doi.org/10.1016/j.ccell.2018.08.008Razavi P., Chang M.T., Xu G., Bandlamudi C., Ross D.S., Vasan N., Cai Y., Bielski C.M., Donoghue M.T.A., Jonsson P., Penson A., Shen R., Pareja F., Kundra R., Middha S., Cheng M.L., Zehir A., Kandoth C., Patel R., Huberman K., Smyth L.M., Jhaveri K., Modi S., Traina T.A., Dang C., Zhang W., Weigelt B., Li B.T., Ladanyi M., Hyman D.M., Schultz N., Robson M.E., Hudis C., Brogi E., Viale A., Norton L., Dickler M.N., Berger M.F., Iacobuzio-Donahue C.A., Chandarlapaty S., Scaltriti M., Reis-Filho J.S., Solit D.B., Taylor B.S., Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34 (3): 427-438. https://doi.org/10.1016/j.ccell.2018.08.008Rong J., Xie X., Niu Y., Su Z. Correlation between the RNA Expression and the DNA Methylation of Estrogen Receptor Genes in Normal and Malignant Human Tissues. Curr. Issues. Mol. Biol. 2024; 46 (4): 3610-3625. https://doi.org/10.3390/cimb46040226Rong J., Xie X., Niu Y., Su Z. Correlation between the RNA Expression and the DNA Methylation of Estrogen Receptor Genes in Normal and Malignant Human Tissues. Curr. Issues. Mol. Biol. 2024; 46 (4): 3610-3625. https://doi.org/10.3390/cimb46040226Saatci O., Huynh-Dam K.T., Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J. Mol. Med. (Berl). 2021; 99 (12): 1691-1710. https://doi.org/10.1007/s00109-021-02136-5Saatci O., Huynh-Dam K.T., Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J. Mol. Med. (Berl). 2021; 99 (12): 1691-1710. https://doi.org/10.1007/s00109-021-02136-5Shen Y.T., Huang X., Zhang G., Jiang B., Li C.J., Wu Z.S. Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis. Front Oncol. 2021; 11: 636365. https://doi.org/10.3389/fonc.2021.636365Shen Y.T., Huang X., Zhang G., Jiang B., Li C.J., Wu Z.S. Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis. Front Oncol. 2021; 11: 636365. https://doi.org/10.3389/fonc.2021.636365Tanim M.T.H., Nath S.D., Khan S.F., Khan A., Sajib A.A. Transcriptomes of cervical cancer provide novel insights into dysregulated pathways, potential therapeutic targets, and repurposed drugs. Cancer Treat. Res. Commun. 2024; 39: 100808. https://doi.org/10.1016/j.ctarc.2024.100808Tanim M.T.H., Nath S.D., Khan S.F., Khan A., Sajib A.A. Transcriptomes of cervical cancer provide novel insights into dysregulated pathways, potential therapeutic targets, and repurposed drugs. Cancer Treat. Res. Commun. 2024; 39: 100808. https://doi.org/10.1016/j.ctarc.2024.100808Yuan J., Wen M., Matnuri A., Zhao S., Jian N., Shen G. The expression of lnc-CCDC170-4:1, ESR1, lncRNA SRA, and CYP19A1 in cervical squamous cell carcinoma and their relationship with the clinical characteristics. Front. Oncol. 2024; 14: 1430826. https://doi.org/10.3389/fonc.2024.1430826Yuan J., Wen M., Matnuri A., Zhao S., Jian N., Shen G. The expression of lnc-CCDC170-4:1, ESR1, lncRNA SRA, and CYP19A1 in cervical squamous cell carcinoma and their relationship with the clinical characteristics. Front. Oncol. 2024; 14: 1430826. https://doi.org/10.3389/fonc.2024.1430826

The authors declare that there are no conflicts of interest present.